Coherus BioSciences (CHRS) Misses Q2 EPS by 60c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.35 +9.76%
Revenue Growth %: +37.8%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +37.8%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($1.71), $0.60 worse than the analyst estimate of ($1.11). Revenue for the quarter came in at $844 thousand, versus $10.2 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Arrive AI and DXC Technology partner to bring delivery tech to factories
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
